Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07763652 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Name: A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors — clinical trial record (NCT07763652)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSichuan Baili Pharmaceutical Co., Ltd.

Started2026-09-10

View on ClinicalTrials.gov ↗

Amendment history

2026-08-25

Study Status, Contacts/Locations v1

Recruitment opened

Study sitescontacts updated at 1 of 1 site

2026-08-10

Original filing

Sichuan Baili Pharmaceutical Co., Ltd.

135 trials monitored

See 14 trials at risk

This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-ARC002 Injection in patients with locally advanced or metastatic solid tumors.

Trial Details

NCT Number	NCT07763652
Lead Sponsor	Sichuan Baili Pharmaceutical Co., Ltd. Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions	Gastrointestinal Tumors, Solid Tumors
Enrollment	22 participants
Start Date	2026-09-10
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-22